Appointment dossier — Colon Cancer

Compounds studied in Colon Cancer

Compounds named in the cited literature for Colon Cancer, labeled by the strongest evidence found:

• Adjuvant chemotherapy (ACT) — Meta-analysis
• Capecitabine and oxaliplatin — Meta-analysis
• Fluorouracil, leucovorin, and oxaliplatin — Meta-analysis
• Oxaliplatin (addition to fluoropyrimidine-based ACT) — Meta-analysis
• Oxaliplatin-containing chemotherapy — Meta-analysis
• Oxaliplatin-containing chemotherapy (duration) — Meta-analysis
• 5-FU-based adjuvant therapy — Named in the literature
• 5-FU/leucovorin/oxaliplatin therapy — Named in the literature
• BRAF V600E-targeted therapy — Named in the literature
• checkpoint inhibitors — Named in the literature
• colonic stenting — Named in the literature
• colonoscopy — Named in the literature
• complete mesocolic excision (CME) — Named in the literature
• computed tomography colonography — Named in the literature
• en bloc resection — Named in the literature
• endoscopic surveillance — Named in the literature
• flexible sigmoidoscopy — Named in the literature
• HER2-targeted therapy — Named in the literature
• irinotecan (bolus) — Named in the literature
• standard high-quality right hemicolectomy — Named in the literature
• stool-based tests — Named in the literature
• surgical resection of liver or lung metastases — Named in the literature
• systemic therapy — Named in the literature
• thrombopoietin receptor agonists (TPO-RAs) — Named in the literature

Open recruiting trials (18)

• NCT07405476 · Phase 2 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment (United States)
• NCT06200831 — Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases (Norway)
• NCT06057350 — Surgery Versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR (Norway)
• NCT06434896 — Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial (Netherlands)
• NCT06179602 — Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors (Netherlands)
• NCT03755739 · Phase 2 / Phase 3 — Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors (China)
• NCT07070518 · Phase 1 / Phase 2 — Study of GV20-0251 in Participants With Solid Tumor Malignancies (China)
• NCT01174121 · Phase 2 — Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (United States)
• NCT06386146 · Phase 1 / Phase 2 — JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation (United States)
• NCT04851119 · Phase 1 / Phase 2 — Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (United States)
• NCT07477522 · Phase 1 — Effects of High-Fiber Diet on Gut Microbiota, Metabolism, and Immune Microenvironment in Solid Tumor Patients: A Clinical Study (China)
• NCT06771219 · Phase 1 — SLV-154 Treatment of Metastatic Solid Tumors (United States)
• NCT06666270 · Phase 1 — Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors (China)
• NCT05148494 · Phase 4 — TES RCT Fleet Enema vs Oral Mechanical Bowel Prep (Canada)
• NCT05606692 · Phase 4 — Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) (Taiwan)
• NCT05797467 · Phase 3 — Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients (China)
• NCT06836128 · Phase 3 — The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients (Egypt)
• NCT06343870 · Phase 3 — Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME) (Brazil)

Most-relevant first: trials that name Colon Cancer, then broader trials you may still qualify for. 1198 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Financial help to look into

• PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
• HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
• CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
• Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
• NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/

Questions to ask your oncologist

1. I've read that Adjuvant chemotherapy (ACT) has been studied in people for Colon Cancer — what's the evidence, and is it an option or available in a trial for me?
2. I've read that Capecitabine and oxaliplatin has been studied in people for Colon Cancer — what's the evidence, and is it an option or available in a trial for me?
3. I've read that Fluorouracil, leucovorin, and oxaliplatin has been studied in people for Colon Cancer — what's the evidence, and is it an option or available in a trial for me?
4. Of the open trials I found (for example NCT07405476), am I eligible for any — here or at a larger cancer center?
5. What is my exact diagnosis — the type, subtype, stage, and grade?
6. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
7. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
8. What is the goal of treatment for me — cure, long-term control, or comfort?
9. What are all of my standard treatment options, and what does each one involve?
10. What is the realistic benefit of each option, in actual numbers?
11. What are the most common and the most serious side effects, and how are they managed?
12. How will we know if treatment is working, and how often will I be scanned or tested?
13. If the first treatment doesn't work, what are the next options?
14. Are there gentler options if I want to prioritize quality of life?
15. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
16. Is my case reviewed by a multidisciplinary tumor board?
17. Would a second opinion at a center that treats my cancer often be worthwhile?
18. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
19. Which symptoms are emergencies, and who do I call after hours?
20. Should I see palliative or supportive care alongside my treatment?
21. How will treatment affect my daily life, work, and (if it matters to me) fertility?
22. What can I safely do myself — diet and activity — and is anything I'm taking risky?